Suma Satti

TL;DR: BAP1- or SETD2-mutated ccRCCs have been associated with poor overall survival, while PBRM1 mutations seem to identify a favorable group ofccRCC tumors.

TL;DR: Nearly 3 out of 4 mCRC patients experienced MFH despite access to health insurance, underscoring the need for clinic and policy solutions that protect cancer patients from financial harm.

TL;DR: Clinical data is retrospectively reviewed on consecutive patients treated with targeted therapy for mRCC diagnosed >5 years after nephrectomy with curative intent to analyze clinicopathologic features and response to targeted therapy in patients with late-relapse metastatic RCC.

TL;DR: FOLFOX is used as an alternative for older patients and patients with poor performance status based on retrospective observation of FOLFOX in metastatic/advanced pancreatic adenocarcinoma and FOLFIRINOX has been increasingly used as neoadjuvant chemotherapy, but may not be well tolerated especially in older patients due to adverse effect profile.

TL;DR: The financial impact of rising cancer care costs contribute to “financial toxicity” in cancer pts is unknown and no studies, to the knowledge, have prospectively assessed the financial impact.